Study on Predictive Parameters of Liver Fibrosis Risk in Patients with Metabolic Dysfunction-associated Fatty Liver Disease Complicated with Chronic Hepatitis B

Yixin WANG; Fang WANG; Xiangyan WEI; Haiyang JIANG; Airong CHEN

doi:10.12259/j.issn.2095-610X.S20251015

Volume 46 Issue 10

Oct. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(10): 121-128

Yixin WANG, Fang WANG, Xiangyan WEI, Haiyang JIANG, Airong CHEN. Study on Predictive Parameters of Liver Fibrosis Risk in Patients with Metabolic Dysfunction-associated Fatty Liver Disease Complicated with Chronic Hepatitis B[J]. Journal of Kunming Medical University, 2025, 46(10): 121-128. doi: 10.12259/j.issn.2095-610X.S20251015

Citation:

Yixin WANG, Fang WANG, Xiangyan WEI, Haiyang JIANG, Airong CHEN. Study on Predictive Parameters of Liver Fibrosis Risk in Patients with Metabolic Dysfunction-associated Fatty Liver Disease Complicated with Chronic Hepatitis B[J]. Journal of Kunming Medical University, 2025, 46(10): 121-128. doi: 10.12259/j.issn.2095-610X.S20251015

Citation:

Yixin WANG, Fang WANG, Xiangyan WEI, Haiyang JIANG, Airong CHEN. Study on Predictive Parameters of Liver Fibrosis Risk in Patients with Metabolic Dysfunction-associated Fatty Liver Disease Complicated with Chronic Hepatitis B[J]. Journal of Kunming Medical University, 2025, 46(10): 121-128. doi: 10.12259/j.issn.2095-610X.S20251015

PDF( 772 KB)

Study on Predictive Parameters of Liver Fibrosis Risk in Patients with Metabolic Dysfunction-associated Fatty Liver Disease Complicated with Chronic Hepatitis B

doi: 10.12259/j.issn.2095-610X.S20251015

1.
The Second Clinical Medical College，Lanzhou University，Lanzhou Gansu 730000
2.
Children's Kindergarten Education Center，Gansu Provincial Maternity and Child-care Hospital‌，Lanzhou Gansu 730000
3.
Department of Urology，Peking University Cancer Hospital Yunnan/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650000
4.
Department of Endocrinology and Metabolism，The Second Hospital of Lanzhou University，Lanzhou Gansu 730030，China

Received Date: 2025-03-11
Publish Date: 2025-10-28

Abstract

Abstract

Objective To explore the influencing factors of liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease （MAFLD） complicated with chronic hepatitis B （CHB）, and to find clinically convenient predictive parameters for assessing liver fibrosis risk. Methods A retrospective analysis was conducted on 221 cases of MAFLD with CHB diagnosed and treated at the Second Hospital of Lanzhou University between January 2015 and August 2022. Patients were divided into low-risk （FIB-4<1.30, n = 84）, medium-risk （1.30≤FIB-4≤2.67, n = 94） and high-risk （FIB-4>2.67, n = 43） liver fibrosis groups based on the Fibrosis-4 （FIB-4） index. General clinical data, laboratory indicators and composite indicators were compared among the three groups. Variables were screened using forward stepwise regression, and binary logistic regression analysis was performed to determine independent predictors of liver fibrosis. A prediction model was constructed and evaluated using receiver operating characteristic （ROC） curve analysis. Results Age, AST and Triglyceride-glucose index（TyG） were independent risk factors for liver fibrosis in patients with MAFLD combined with CHB, while platelet-to-lymphocyte ratio （PLR） was an independent protective factor （all P < 0.05）. ROC curve analysis showed that the area under the curve （AUC） for age, AST, TyG, PLR, age-AST and AST-TyG in predicting liver fibrosis were 0.668, 0.764, 0.680, 0.738, 0.856 and 0.805, respectively. At the optimal cut-off values, the sensitivities were 86.0%, 67.4%, 93.0%, 62.8%, 86.0% and 79.1%, and the specificities were 43.3%, 82.0%, 51.7%, 86.0%, 71.3% and 70.2%. Conclusion Age, AST, TyG and PLR are influencing factors of liver fibrosis in MAFLD combined with CHB patients. The parameters established based on these factors may predict the risk of liver fibrosis, and combined prediction can improve predictive efficacy.
- Metabolic dysfunction-associated fatty liver disease,
- Chronic hepatitis B,
- Liver fibrosis,
- Triglyceride-glucose index,
- Platelet-to-lymphocyte ratio

FullText(HTML)

References(28)

References

[1]	罗小露, 谢宝刚, 邱芳, 等. 慢性乙型肝炎患者抗病毒治疗不同阶段HBV RNA的检测及意义[J]. 中国感染与化疗杂志, 2022, 22(3): 289-294.
[2]	Davis T. Diabetes and metabolic dysfunction-associated fatty liver disease[J]. Metabolism: Clinical and Experimental, 2021, 123: 154868. doi: 10.1016/j.metabol.2021.154868
[3]	Campos-Murgu í a A, Ruiz-Marg á in A, Gonz á lez-Regueiro J A, et al. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease[J]. World Journal of Gastroenterology, 2020, 26(39): 5919-5943. doi: 10.3748/wjg.v26.i39.5919
[4]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. doi: 10.3969/j.issn.1001-5256.2018.05.007
[5]	范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[6]	尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(3): 457-478.
[7]	Yan X, Jiahui X, Man L, et al. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters[J]. Frontiers in Endocrinology, 2022, 13: 951689. doi: 10.3389/fendo.2022.951689
[8]	黄媞, 戴霞, 张莉莉, 等. 高血压合并2型糖尿病患者颈动脉内-中膜增厚的影响因素和甘油三酯-葡萄糖指数评估颈动脉内-中膜增厚的价值研究[J]. 内科, 2023, 18(1): 14-17+32.
[9]	Ramdas Nayak V K, Satheesh P, Shenoy M T, et al. Triglyceride Glucose (TyG) Index: A surrogate biomarker of insulin resistance[J]. The Journal of the Pakistan Medical Association, 2022, 72(5): 986-988. doi: 10.47391/JPMA.22-63
[10]	乔晶, 刘乙君, 王彦. 甘油三酯-葡萄糖指数与胰岛素抵抗相关代谢性疾病的关系[J]. 国际内分泌代谢杂志, 2022, 42(3): 223-226. doi: 10.3760/cma.j.cn121383-20210206-02013
[11]	努尔吉马·阿合尼牙孜, 刘一佳, 梁灿灿, 等. 甘油三酯葡萄糖指数与非酒精性脂肪性肝病脂肪变程度及肝纤维化的相关性研究[J]. 海南医学院学报, 2023, 29(23): 1794-1800.
[12]	Eslam M, Sanyal J A, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1.
[13]	Helda T, Fatemeh N, Alireza O. Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study[J]. Clinical Nutrition ESPEN, 2021, 44: 483-487. doi: 10.1016/j.clnesp.2021.04.025
[14]	赵玲玲, 王贝贝, 姚勇利, 等. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(3): 356-359. doi: 10.3969/j.issn.1672-5069.2023.03.014
[15]	赵晨, 姜美玲, 邱懿雯. 肝纤维化血清学和影像学诊断的研究进展[J]. 国际消化病杂志, 2024, 44(1): 13-16+35. doi: 10.3969/j.issn.1673-534X.2024.01.004
[16]	Martina C, Dominik S, Carsten D, et al. Macrophages and platelets in liver fibrosis and hepatocellular carcinoma[J]. Frontiers in Immunology, 2023, 14: 1277808. doi: 10.3389/fimmu.2023.1277808
[17]	赵芯, 李晖, 邓秀秀, 等. 抗血小板药物与肝纤维化[J]. 实用医学杂志, 2024, 40(8): 1083-1087. doi: 10.3969/j.issn.1006-5725.2024.08.011
[18]	Chauhan A, Adams D H, Watson S P, et al. Platelets: No longer bystanders in liver disease[J]. Hepatology, 2016, 64(5): 1774-1784. doi: 10.1002/hep.28526
[19]	薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. doi: 10.3969/j.issn.1001-5256.2020.06.007
[20]	Ayman A, Mostafa E, Imam W. Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease[J]. European Journal of Gastroenterology & Hepatology, 2018, 30(2): 207-211.
[21]	牛兴杰, 刘志慧, 崔凤梅, 等. 相关炎症指标预测慢性乙型肝炎患者肝纤维化程度的价值[J]. 中华医院感染学杂志, 2020, 30(5): 703-708.
[22]	Cornberg M, Wong V W, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol, 2017, 66(2): 398-411. doi: 10.1016/j.jhep.2016.08.009
[23]	Paccoud O, Surgers L, Lacombe K. Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach[J]. Rev Med Interne, 2019, 40(9): 590-598. doi: 10.1016/j.revmed.2019.03.333
[24]	谢放, 孟庆华, 侯维, 等. HBeAg阳性慢性乙型肝炎合并非酒精性脂肪肝患者的临床与病理学特征[J]. 中华实验和临床感染病杂志(电子版), 2018, 12(3): 256-261.
[25]	Chen Y, Fan C, Chen Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study[J]. Oncotarget, 2017, 8(35): 58601-58610. doi: 10.18632/oncotarget.17380
[26]	刘伟鸿, 刘晖, 丁惠国, 等. 慢性乙型肝炎合并代谢相关性脂肪性肝病的临床特征及预后影响因素分析[J]. 临床肝胆病杂志, 2022, 38(10): 2230-2235. doi: 10.3969/j.issn.1001-5256.2022.10.007
[27]	阳韬, 李军. 慢性乙型肝炎合并非酒精性脂肪性肝病: 当前的认识与争议[J]. 临床肝胆病杂志, 2023, 39(8): 1797-1804.
[28]	Xuan Y, Wu D, Zhang Q, et al. Elevated ALT/AST ratio as a marker for NAFLD risk and severity: Insights from a cross-sectional analysis in the United States[J]. Frontiers in Endocrinology, 2024, 15: 1457598. doi: 10.3389/fendo.2024.1457598

Relative Articles(20)

Relative Articles

[1]	Rui YIN, Guowei MA, Wenxi YUE, Haixia GU, Ying ZHOU, Jie CHEN. Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B. Journal of Kunming Medical University, 2025, 46(6): 79-88. doi: 10.12259/j.issn.2095-610X.S20250610
[2]	Hong ZHU, Qiong DU, Zhengwei ZHAO, Liping CHEN, Muli XU, Yungui TU. Analysis of Blood Cells and Establishment of Reference Interval of Elderly Derivative Index in Anning Area of Yunnan Province. Journal of Kunming Medical University, 2024, 45(6): 145-153. doi: 10.12259/j.issn.2095-610X.S20240620
[3]	Chunyan CHEN, Zimian FAN. Correlation Analysis of Peripheral Blood SAA/CRP and NLR Levels with HBV-DNA Lload and Degree of Disease in CHB Patients. Journal of Kunming Medical University, 2024, 45(5): 144-150. doi: 10.12259/j.issn.2095-610X.S20240522
[4]	Yongrui YANG, Liyuan WANG, Haiwen LI, Zhirong ZHAO, Rui PU, Guishuai WU, Shude LI. Scutellarin Ameliorates Liver Fibrosis in Nonalcoholic Fatty Liver Disease by Inhibiting NOX Expression. Journal of Kunming Medical University, 2022, 43(7): 38-45. doi: 10.12259/j.issn.2095-610X.S20220721
[5]	Yegang HU, Wei ZHANG. Role of Hereditary T Lymphocyte Immune Deficiency in Pulmonary Fibrosis Induced by Paraquat. Journal of Kunming Medical University, 2022, 43(4): 6-11. doi: 10.12259/j.issn.2095-610X.S20220402
[6]	Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711
[7]	Di HE, Peng CHEN, Feng LIU, Yang XU, Lei HAN, Wenjing DING. Progress in Etiology and Pathogenesis of Liver Fibrosis. Journal of Kunming Medical University, 2022, 43(11): 165-171. doi: 10.12259/j.issn.2095-610X.S20221122
[8]	Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331
[9]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[10]	Qin XIE, Yan-ping LIANG, Yin ZHANG, Zeng-hui XU, Li-ying YOU. Efficacy of Multiple Non-invasive Diagnostic Models in the Diagnosis of Hepatic Fibrosis in Patients with Chronic Liver Diseases. Journal of Kunming Medical University, 2021, 42(7): 115-120. doi: 10.12259/j.issn.2095-610X.S20210719
[11]	Pu Dong , Li Xiao Fei , Yu Ting Ting , Wang Hong Ying , Zhang Run Wu , Li Li Hua , Bai Jing , Ding Cai Mei , Li Dong Ling , Yang Yong Rui . . Journal of Kunming Medical University, 2020, 41(06): 149-155.
[12]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[13]	Xie Wei , Zhao Chuan , Wang Rong , Wang Wen Ping , Tu Hong . . Journal of Kunming Medical University, 2020, 41(02): 82-86.
[14]	Sun Yue , Wei Jia , Lu Yong Ping , Wang Jin , Zou Yu , Wang Yu Xue , Yang Mi . Quantitative Analysis on Staging of Chronic Viral Hepatitis B and Hepatic Fibrosis by Real-time Shear Wave Elastography. Journal of Kunming Medical University, 2016, 37(11): 55-59.
[15]	Ning Lin . . Journal of Kunming Medical University,
[16]	He Min . . Journal of Kunming Medical University,
[17]	Liu Dong . . Journal of Kunming Medical University,
[18]	Li Ming Ming . . Journal of Kunming Medical University,
[19]	Su Ying . . Journal of Kunming Medical University,
[20]	Zeng Jin . . Journal of Kunming Medical University,